Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
Joan Carles, Emilio Esteban, M Climent et al. · Annals of Oncology · 2007
Cited by 59 works. doi:10.1093/annonc/mdm160 Open-access PDF
Authors
- Joan Carles
- Emilio Esteban
- Albert Font Pous
- J.L. González-Larriba
- Alfonso Berrocal
- Ignacio Garcia‐Ribas
- X. Marfà
- Xavier Fabregat
- Joan Albanell
- Joaquim Bellmunt B
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Prediction of Creatinine Clearance from Serum Creatinine
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
- Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
- A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
- Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy